1. Home
  2. URGN vs ASM Comparison

URGN vs ASM Comparison

Compare URGN & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$18.44

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Logo Avino Silver & Gold Mines Ltd. (Canada)

ASM

Avino Silver & Gold Mines Ltd. (Canada)

HOLD

Current Price

$6.84

Market Cap

920.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
URGN
ASM
Founded
2004
1968
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Mining
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
920.7M
IPO Year
2016
2005

Fundamental Metrics

Financial Performance
Metric
URGN
ASM
Price
$18.44
$6.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$29.29
$8.18
AVG Volume (30 Days)
816.7K
4.2M
Earning Date
06-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,128,000.00
N/A
Revenue This Year
$119.37
$35.91
Revenue Next Year
$64.79
$62.02
P/E Ratio
N/A
$67.93
Revenue Growth
N/A
N/A
52 Week Low
$3.42
$1.37
52 Week High
$30.00
$11.99

Technical Indicators

Market Signals
Indicator
URGN
ASM
Relative Strength Index (RSI) 39.66 36.12
Support Level $16.47 $3.70
Resistance Level $20.44 $9.70
Average True Range (ATR) 1.45 0.56
MACD -0.18 -0.25
Stochastic Oscillator 13.89 0.69

Price Performance

Historical Comparison
URGN
ASM

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About ASM Avino Silver & Gold Mines Ltd. (Canada)

Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.

Share on Social Networks: